Matever 100 mg/ml concentrate for solution for infusion
Authorisation EU/1/11/711/030 · Pharmathen S.A.
- Licence holder
- Pharmathen S.A. (all products →)
- Active substance
- Levetiracetam
- Clinical trials
- 14 clinical trials →
- Dosage form
- Concentrate for solution for infusion
- Route of administration
- Oral use
- ATC codes
- N03AX, N03AX14
- First authorised
- 03/10/2011
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Generic application (Article 10(1) of Directive No 2001/83/EC)
Levetiracetam: supply and approvals
45 authorised products on the HPRA list contain Levetiracetam. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 19 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 19 Nov 2026)
- Germany (BfArM)
- 20 supply notices, e.g. Levetiracetam HEXAL 100 mg/ml Konzentrat zur Herstellung einer Infusionslösung (6 Jul 2026 to 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 711. It has been authorised for 15 years (since 3 October 2011). The HPRA list does not say whether it is on sale.
Other medicines with Levetiracetam in Ireland
44 other products on the HPRA list contain Levetiracetam, from 15 licence holders; 5 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Levetiracetam 100 mg/ml Concentrate for solution for infusion | Noridem Enterprises Limited | National authorisation (PA) | Marketed |
| Levetiracetam Clonmel 1000 mg film-coated tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Levetiracetam Clonmel 250 mg film-coated tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Levetiracetam Clonmel 500 mg film-coated tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Levetiracetam Thame 100 mg/ml oral solution | Syri Pharma Limited t/a Thame Laboratories | National authorisation (PA) | Marketed |
| Keppra 100 mg/ml concentrate for solution for infusion | UCB Pharma S.A. | Centralised EU authorisation | Not stated |
| Keppra 100 mg/ml oral solution | UCB Pharma S.A. | Centralised EU authorisation | Not stated |
| Keppra 1000 mg film-coated tablets | UCB Pharma S.A. | Centralised EU authorisation | Not stated |
| Keppra 250 mg film-coated tablets | UCB Pharma S.A. | Centralised EU authorisation | Not stated |
| Keppra 500 mg film-coated tablets | UCB Pharma S.A. | Centralised EU authorisation | Not stated |
| Keppra 750 mg film-coated tablets | UCB Pharma S.A. | Centralised EU authorisation | Not stated |
| Larofec 1000 mg film-coated granules in sachet | C4 health GmbH | National authorisation (PA) | Not marketed |
Other substances in ATC group N03AX
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 11 other active substances share the group N03AX with this product:
Pregabalin (34) · Lamotrigine (26) · Lacosamide (12) · Topiramate (10) · Perampanel (7) · Cenobamate (5) · Stiripentol (4) · Zonisamide (3) · CANNABIDIOL (1) · Fenfluramine hydrochloride (1) · Ganaxolone (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Pharmathen S.A. holds 16 products on the HPRA list, with 5 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.